NanoViricides Inc (NYSEAMERICAN: NNVC) recently caught my attention as a potential big win in the COVID-19 space. The small biotech is up to big things that could just be key in the fight against the virus causing the pandemic. However, this is no one-trick pony, even when covid is under control or eradicated, there’s plenty of value in the company’s tech.
What’s The Story Behind NNVC Stock?
Founded in 2005, NanoViricides has been working for more than a decade to develop antiviral treatments that are like nothing on the market today. The treatment candidates being developed are all centered around the company’s nanoviricide technology.
So, what are nanoviricides? They’re an antiviral technology that attacks virus-infected cells in an entirely new way, one in which drug resistance is highly unlikely even as a virus mutates.
Importantly, a nanoviricide looks just like a human cell to viruses. These nanoviricides are large enough for viral particles to latch on to them while being small enough to circulate through the human body. Once a virus particle does decide to latch on, the virus particle does not need to enter the nanoviricide. Instead, the antiviral technology wraps around the particle, encapsulates it, and destroys it.
Obvious Indications In The Current COVID-19 Pandemic
Given how effective the method of treating viral infections that’s being developed by NNVC is proving to be, there is an obvious connection between the work that the company is doing and the potential to use its technology to treat SARS-CoV-2, the virus that causes COVID-19.
As mentioned above, it is believed that nanoviricides will attract virus particles in novel coronavirus patients. Once attracted, the treatment is expected to wrap around these particles and begin to destroy them. Of course, this opens the door to several key advantages ahead:
- Speed To Market – In general biotechnologies take millions of dollars to develop and years to make it from candidate to commercialization. However, the world is in a panic, looking for options to treat COVID-19, pushing regulatory authorities to move quickly, funds to be available to speed up development, and other benefits to those working in the space. With a potential COVID-19 treatment, NNVC could see its nanoviricides reach the market relatively quickly.
- Potential Funding – The COVID-19 pandemic is leading to a flood of funds being provided by both public and private agencies in an attempt fight the pandemic back. As a result, NanoViricides may be the beneficiary of one or more of many financial programs that we’re seeing hit the tape.
- Revenue – Of course, should the company bring its nanoviricides to market, the move would likely generate significant revenue. After all, with the novel coronavirus claiming the lives of so many victims, demand for a treatment is incredibly high.
Moreoveer, the company just released news announcing that it has developed to nanovericides that have proven to be effective against the coronavirus. Read the news here.
NanoViricides Beyond COVID-19
The COVID-19 space is a hot one at the moment, and for good reason. The pandemic is changing the shape of life as we know it, with social distancing leading to increasing uncomfort in an overwhelmngly social society.
The good news is that COVID-19 is not something that’s likely to be around forever. Of course, it’s the hot topic in the investing space, but in time, those who rely solely on work in the space will likely fall flat. The good news is that NNVC is far from a one-trick pony.
The company’s nanoviricides are expected to be effective in a wide range of indications. First of these is the Company’s HerpeCide™ program.
Some of these indications include both injectible and oral influenza drugs that are expected to be effective regardless of mutations. The company is also working on options to treat HIV, dengue, shingles and other ailments.
So, should the company hit it big in COVID-19, it will only act as a runway to bring other highly valuable treatments to market. So, just how valuable can this be?
The Market Potential Is Incredible
With its nanoviricides, NNVC is embarking on several incredibly valuable markets. Just take a look below:
- COVID-19 – To date, the market size has yet to be determined here, but I would imagine that the treatment market for the novel coronavirus is in the billions.
- HIV – The HIV treatment market is expected to grow to be worth more than $40 billion annually by the year 2026.
- Influenza – The influenza treatment market is expected to grow to be worth more than $1 billion annually by the year 2026.
- Dengue – The market that surrounds the treatment of dengue is expected to grow to be worth nearly $4 billion annually by 2025.
- Shingles – It is expected that the Shingles market will grow to be worth more than $1 billion annually in the near term.
The bottom line is that if NNVC is successful in any of the many indications that it is attacking with its nanoviricides, the market potential would be incredible.
The bottom line here is simple. NanoViricides is a stock that should be on your watch list. In today’s environment, antiviral treatments are losing efficacy as viruses become more resistant to drugs available on the market. With the company’s nanoviricide technology, this drug resistance may be a thing of the past.
With multiple candidates being assessed in multiple high value indications, including COVID-19, shingles, influenza, HIV and others, there are several catalysts ahead, making NNVC a stock that’s hard to ignore.
[vc_row full_width=”stretch_row_content td-stretch-content”][vc_column][tdm_block_hero title_text=”R2V0JTIwRnJlZSUyMEFsZXJ0cw==” title_size=”tdm-title-bg” description=”Sm9pbiUyMG91ciUyMGZyZWUlMjBtYWlsaW5nJTIwbGlzdCUyMHRvJTIwcmVjZWl2ZSUyMHN0b2NrJTIwYWxlcnRzIQ==” button_text=”Join Our Mailing List Here” button_tdicon=”tdc-font-fa tdc-font-fa-chevron-right” button_url=”https://alphastocknews.us4.list-manage.com/subscribe?u=92a9c8ec6acba6727f3eff17d&id=b717e1440e” tds_button=”tds_button3″ button_size=”tdm-btn-lg” button_tdicon-1=”tdc-font-fa tdc-font-fa-search” tds_button-1=”tds_button3″ button_size-1=”tdm-btn-lg” block_width=”1200″ content_align_horizontal=”content-horiz-center” content_align_vertical=”content-vert-center” background=”eyJ0eXBlIjoiZ3JhZGllbnQiLCJjb2xvcjEiOiJyZ2JhKDIyLDExMiwxOTEsMC44NSkiLCJjb2xvcjIiOiJyZ2JhKDAsMCwwLDAuODUpIiwibWl4ZWRDb2xvcnMiOltdLCJjc3MiOiJiYWNrZ3JvdW5kOiAtd2Via2l0LWxpbmVhci1ncmFkaWVudCgwZGVnLHJnYmEoMCwwLDAsMC44NSkscmdiYSgyMiwxMTIsMTkxLDAuODUpKTtiYWNrZ3JvdW5kOiBsaW5lYXItZ3JhZGllbnQoMGRlZyxyZ2JhKDAsMCwwLDAuODUpLHJnYmEoMjIsMTEyLDE5MSwwLjg1KSk7IiwiY3NzUGFyYW1zIjoiMGRlZyxyZ2JhKDAsMCwwLDAuODUpLHJnYmEoMjIsMTEyLDE5MSwwLjg1KSJ9″][/vc_column][/vc_row]
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and NanoViricides, CNA Finance has been hired to develop and publicly disseminate information about NNVC via Websites and Email in exchange for one thousand five hundred dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and NanoViricides has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.